Delgado E, Luque M A, Alcántara A, Trapote M A, Clemente F, Galera C, Valverde I, Villanueva-Peñacarrillo M L
Fundación Jiménez Díaz, Departamento de Metabolismo, Nutricón y Hormonas, Madrid, Spain.
Peptides. 1995;16(2):225-9. doi: 10.1016/0196-9781(94)00175-8.
We have found [125I]glucagon-like peptide-1(7-36)-amide-specific binding activity in rat skeletal muscle plasma membranes, with an estimated M(r) of 63,000 by cross-linking and SDS-PAGE. The specific binding was time and membrane protein concentration dependent, and displaceable by unlabeled GLP-1(7-36)-amide with an ID50 of 3 x 10(-9) M of the peptide; GLP-1(1-36)-amide also competed, whereas glucagon and insulin did not. GLP-1(7-36)-amide did not modify the basal adenylate cyclase activity in skeletal muscle plasma membranes. These data, together with our previous finding of a potent glycogenic effect of GLP-1(7-36)-amide in rat soleus muscle, and also in isolated hepatocytes, which was not accompanied by a rise in the cell cyclic AMP content, lead use to believe that the insulin-like effects of this peptide on glucose metabolism in the muscle could be mediated by a type of receptor somehow different to that described for GLP-1 in pancreatic B cells, where GLP-1 action is mediated by the cyclic AMP-adenylate cyclase system.
我们在大鼠骨骼肌质膜中发现了[125I]胰高血糖素样肽-1(7 - 36)-酰胺特异性结合活性,通过交联和SDS - PAGE估计其分子量为63,000。特异性结合具有时间和膜蛋白浓度依赖性,可被未标记的GLP - 1(7 - 36)-酰胺取代,该肽的半数抑制浓度(ID50)为3×10(-9) M;GLP - 1(1 - 36)-酰胺也有竞争作用,而胰高血糖素和胰岛素则无。GLP - 1(7 - 36)-酰胺未改变骨骼肌质膜中的基础腺苷酸环化酶活性。这些数据,连同我们之前发现的GLP - 1(7 - 36)-酰胺在大鼠比目鱼肌以及分离的肝细胞中具有强大的糖原生成作用,且不伴随细胞环磷酸腺苷(cAMP)含量升高,使我们相信该肽对肌肉葡萄糖代谢的胰岛素样作用可能由一种与胰腺β细胞中描述的GLP - 1受体不同的受体介导(在胰腺β细胞中,GLP - 1的作用由环磷酸腺苷 - 腺苷酸环化酶系统介导)。